BioAge Labs, Inc. (BIOA)
8.18
-0.30
(-3.54%)
USD |
NASDAQ |
Sep 15, 16:00
8.28
+0.10
(+1.22%)
After-Hours: 05:20
BioAge Labs Enterprise Value : 58.54M for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 58.54M |
| September 14, 2026 | 72.28M |
| September 11, 2026 | 72.74M |
| September 10, 2026 | 80.06M |
| September 09, 2026 | 103.86M |
| September 08, 2026 | 114.16M |
| September 04, 2026 | 123.09M |
| September 03, 2026 | 118.97M |
| September 02, 2026 | 129.50M |
| September 01, 2026 | 119.89M |
| August 31, 2026 | 118.97M |
| August 28, 2026 | 125.84M |
| August 27, 2026 | 145.52M |
| August 26, 2026 | 134.53M |
| August 25, 2026 | 146.89M |
| August 24, 2026 | 113.48M |
| August 21, 2026 | 118.06M |
| August 20, 2026 | 127.67M |
| August 19, 2026 | 176.19M |
| August 18, 2026 | 162.92M |
| August 17, 2026 | 160.17M |
| August 14, 2026 | 169.33M |
| August 13, 2026 | 161.54M |
| August 12, 2026 | 163.83M |
| August 11, 2026 | 172.53M |
| Date | Value |
|---|---|
| August 10, 2026 | 208.24M |
| August 07, 2026 | 220.60M |
| August 06, 2026 | 200.00M |
| August 05, 2026 | 186.72M |
| August 04, 2026 | 196.79M |
| August 03, 2026 | 177.56M |
| July 31, 2026 | 97.91M |
| July 30, 2026 | 821.65M |
| July 29, 2026 | 699.88M |
| July 28, 2026 | 687.52M |
| July 27, 2026 | 639.91M |
| July 24, 2026 | 680.65M |
| July 23, 2026 | 686.60M |
| July 22, 2026 | 688.44M |
| July 21, 2026 | 720.94M |
| July 20, 2026 | 705.83M |
| July 17, 2026 | 728.26M |
| July 16, 2026 | 698.51M |
| July 15, 2026 | 723.23M |
| July 14, 2026 | 726.89M |
| July 13, 2026 | 681.34M |
| July 10, 2026 | 798.30M |
| July 09, 2026 | 823.48M |
| July 08, 2026 | 765.80M |
| July 07, 2026 | 801.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.116T |
| Pfizer Inc. | 208.80B |
| Oramed Pharmaceuticals, Inc. | 140.99M |
| Liquidia Corp. | 5.754B |
| Neumora Therapeutics, Inc. | 91.75M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.10M |
| Revenue (Quarterly) | 2.451M |
| Total Expenses (Quarterly) | 28.55M |
| EPS Diluted (Quarterly) | -0.582 |
| Gross Profit Margin (Quarterly) | 97.14% |
| Profit Margin (Quarterly) | -1.06K% |
| Earnings Yield | -29.18% |
| Normalized Earnings Yield | -29.06 |